Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for clinical trials of HRS9531 injection, a novel dual agonist targeting GIPR and GLP-1R, aimed at improving metabolic disorders and weight management [1] Group 1: Product Development - The HRS9531 injection is based on the active ingredient HRS9531, which has global independent intellectual property rights [1] - The drug is designed to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, leading to improved blood sugar levels and weight loss [1] Group 2: Target Indication - HRS9531 injection is expected to provide comprehensive benefits for patients with metabolic dysfunction-related fatty liver disease (MASH) by improving liver lipid accumulation, reducing inflammation, and potentially improving liver fibrosis [1] - There are currently no similar drugs approved for the MASH indication globally [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月12日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-2 ...

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-1780 tablets, which are intended for treating heart failure in adults with left ventricular ejection fraction ≥ 40% [1] Group 1: Company Developments - The subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. will soon initiate clinical trials for HRS-1780 tablets [1] - The total research and development investment for the HRS-1780 project has reached approximately 67.8 million yuan [1] Group 2: Industry Context - HRS-1780 tablets are classified as mineralocorticoid receptor antagonists and are part of a broader category of treatments for heart failure [1] - Current primary medications for heart failure include angiotensin receptor/neprilysin inhibitors and sodium-glucose cotransporter 2 inhibitors [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-201 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司福建盛迪医 ...

Group 1 - The core announcement is that Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-1780 tablets [1] - HRS-1780 is a tablet formulation intended for clinical trials, with the application numbers CXHL2500992 and CXHL2500993 [2] - The approval indicates that HRS-1780 meets the requirements for drug registration as per the Drug Administration Law of the People's Republic of China, allowing the initiation of clinical trials [2] Group 2 - The intended indication for HRS-1780 is the treatment of adult patients with heart failure and a left ventricular ejection fraction of ≥40% [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 孫飄揚先生 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 中國上海 2025年12月12日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 剂 型：片剂 申请事项：临床试验 证券代码：600276 证券简称：恒 ...

Core Insights - The top three companies with the highest short positions are Vanke Enterprises (02202), ZTE Corporation (00763), and COSCO Shipping Holdings (01919), with short ratios of 20.57%, 17.63%, and 17.59% respectively [1][2] - The company with the largest increase in short positions is ZTE Corporation (00763), which saw an increase of 1.96% in its short ratio [1][2] - The companies with the most significant decrease in short positions include UBTECH Robotics (09880), ASMPT (00522), and Vanke Enterprises (02202), with decreases of -3.30%, -1.86%, and -1.83% respectively [1][3] Top 10 Short Position Ratios - Vanke Enterprises (02202) has a short position of 20.57%, down from 22.40% [2] - ZTE Corporation (00763) has a short position of 17.63%, up from 15.67% [2] - COSCO Shipping Holdings (01919) has a short position of 17.59%, up from 15.00% [2] Largest Increases in Short Positions - ZTE Corporation (00763) increased its short position from 15.67% to 17.63%, an increase of 1.96% [2] - Leap Motor (09863) saw its short position rise from 2.79% to 4.58%, an increase of 1.79% [2] - OSL Group (00863) increased its short position from 4.31% to 5.89%, an increase of 1.59% [2] Largest Decreases in Short Positions - UBTECH Robotics (09880) decreased its short position from 5.07% to 1.78%, a decrease of -3.30% [3] - ASMPT (00522) saw its short position drop from 6.71% to 4.85%, a decrease of -1.86% [3] - Vanke Enterprises (02202) reduced its short position from 22.40% to 20.57%, a decrease of -1.83% [3]

Core Insights - The article highlights the top and bottom AH share premium rates as of December 11, with Northeast Electric (00042) leading at a premium rate of 958.82% [1][2]. Summary by Category Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 958.82% with a deviation value of 89.44% [1][2]. - Zhejiang Shibao (01057) follows with a premium rate of 270.15% and a deviation value of 8.43% [2]. - Hongye Futures (03678) ranks third with a premium rate of 265.78% and a deviation value of -2.82% [2]. Bottom AH Share Premium Rates - Contemporary Energy (03750) has the lowest premium rate at -8.28% with a deviation value of 0.95% [1][2]. - China Merchants Bank (03968) follows with a premium rate of -2.31% and a deviation value of -1.80% [2]. - Heng Rui Pharmaceutical (01276) has a premium rate of 1.66% with a deviation value of -1.68% [2]. Top AH Share Deviation Values - Northeast Electric (00042) leads with a deviation value of 89.44% [1][2]. - Red Star Macalline (01528) has a deviation value of 39.65% [2]. - Beijing Machinery (00187) follows with a deviation value of 28.21% [2]. Bottom AH Share Deviation Values - GAC Group (02238) has the lowest deviation value at -22.53% [1][3]. - Shenzhen Expressway (00548) follows with a deviation value of -16.19% [3]. - Jiangsu Ninghu Highway (00177) has a deviation value of -14.92% [3].

Group 1 - The Hong Kong IPO market has raised funds amounting to 2.1 times the total for the entire year of 2024, with expectations for the Hong Kong Stock Exchange to regain the top position in IPO financing by 2025, projecting over HKD 300 billion in IPO fundraising for next year [1] - The trading volume of placement and convertible bond products has significantly increased year-on-year, with major blue-chip companies such as BYD, Xiaomi, Alibaba, China Pacific Insurance, Ping An Insurance, Chow Tai Fook Jewelry, and NIO completing large-scale transactions exceeding USD 1 billion [1] Group 2 - The primary market for Hong Kong stocks is showing a strong recovery, with influential companies actively responding to the national strategy to develop Hong Kong's capital market, leading to the execution of large-scale financing projects [2] - CATL's IPO raised USD 5.3 billion, becoming the largest IPO globally in 2023, and has facilitated other leading companies like Zijin Mining, Sany Heavy Industry, Seres, Hansoh Pharmaceutical, Sanhua Intelligent Controls, Haitian Flavoring and Food, and Chery Automobile to complete financing exceeding USD 1 billion, occupying four spots in the global top ten IPOs [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 建議修訂《公司章程》的背景 建議增加經營範圍 根據本公司實際經營發展需要，本公司擬在經營範圍中增加「藥品包裝材料和藥 品包裝製品的研發、製造與銷售」，並據此修訂《公司章程》相應條文。 建議取消監事會 為遵守《中華人民共和國公司法》（「《公司法》」）、《關於新<公司法>配套制度規則 實施相關過渡期安排》、《上市公司章程指引》、《上海證券交易所股票上市規則》、 上市規則等相關法律、法規、規則及其他規範性文件的規定，結合本公司實際情 況，本公司擬取消本公司監事會（「監事會」），《公司章程》層面規定的監事會職權 將由董事會審計委員會行使。因此，監事會議事規則以及公司管理政策中有關監 事會和本公司監事的規定將被廢除。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 建議修訂《公司章程》 ...